Osivax

Osivax is a clinical-stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary oligodom® technology, designed to induce robust CD8 T-cell responses. Osivax’s mission is to revolutionize flu prevention by leveraging its unique oligodom® technology platform to create a universal flu vaccine that covers current and future flu infections.